TAMIKA COLE: Open Payments
NPI 1366832925 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$440 in 24 payments from 8 companies in 2025. Trend: 2023 $292 · 2024 $335 · 2025 $440
Food & beverage: $440
| Company | Payments | Amount |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | 11 | $147 |
| GlaxoSmithKline, LLC. | 4 | $99 |
| AstraZeneca Pharmaceuticals LP | 3 | $72 |
| PFIZER INC. | 2 | $41 |
| Organon LLC | 1 | $27 |
| Pharming Healthcare, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| GENZYME CORPORATION | 1 | $16 |
Products named: NEFFY, TRELEGY ELLIPTA, TEZSPIRE, PAXLOVID, RUCONEST, AIRSUPRA, ZORYVE, DUPIXENT.
Industry payments across TX — which companies pay providers there.
